PATHOPHYSIOLOGY AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC-RENAL-FAILURE

被引:0
作者
TSUKAMOTO, Y
机构
关键词
PTH; UREMIA; RENAL OSTEODYSTROPHY; 1,25-DIHYDROXYVITAMIN D-3; PULSE THERAPY;
D O I
10.1093/ndt/10.supp3.22
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Following four etiologies are considered as the possible reason for secondary hyperparathyroidism in the previous reports. First, a decreased serum concentration of 1,25(OH)(2)D-3 directly stimulates PTH secretion. Second, hypocalcemia directly stimulates PTH secretion which is independent of 1,25(OH)(2)D-3 action. Third, the presence of decreased calcemic response to PTH. Fourth, there is a strong possibility that hyperphosphatemia indirectly and/or directly may stimulate PTH secretion. The treatment of secondary hyperparathyroidism should be modified according to the stage of uremia. Excess suppression of PTH secretion could cause an adynamic bone disease. Early start of the treatment would be beneficial to prevent the bone from the development of PTH resistance.
引用
收藏
页码:22 / 24
页数:3
相关论文
共 12 条
  • [11] PHARMACOLOGICAL PARATHYROIDECTOMY BY ORAL 1,25(OH)2D3 PULSE THERAPY
    TSUKAMOTO, Y
    NOMURA, M
    MARUMO, F
    [J]. NEPHRON, 1989, 51 (01): : 130 - 131
  • [12] THE ORAL 1,25-DIHYDROXYVITAMIN-D3 PULSE THERAPY IN HEMODIALYSIS-PATIENTS WITH SEVERE SECONDARY HYPERPARATHYROIDISM
    TSUKAMOTO, Y
    NOMURA, M
    TAKAHASHI, Y
    TAKAGI, Y
    YOSHIDA, A
    NAGAOKA, T
    TOGASHI, K
    KIKAWADA, R
    MARUMO, F
    [J]. NEPHRON, 1991, 57 (01): : 23 - 28